More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$336336383
EPS
-0.46
P/E ratio
--
Price to sales
6.96
Dividend yield
--
Beta
0.422625
Previous close
$2.34
Today's open
$2.34
Day's range
$2.26 - $2.48
52 week range
$1.30 - $2.79
show more
CEO
Matthew W. Foehr
Employees
114
Headquarters
Emeryville, CA
Exchange
NASDAQ Global Market
Shares outstanding
144972579
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
OmniAb Q1 Earnings Call Highlights
OmniAb NASDAQ: OABI reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Get OmniAb alerts:Sign UpPartner program progress drives revenue outperformance President and CEO Matt Foehr said the company continues to see partner programs derived from OmniAb's technologies move into the clinic and into later-stage development, which he described as the point where the licensing model translates into “clearer and more visible value” through potential future milestones and royalties.
MarketBeat • May 8, 2026

OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance. “OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidanc.
Business Wire • May 7, 2026

OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.
Zacks Investment Research • May 8, 2026

OmniAb, Inc. (OABI) Q1 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 8, 2026

OmniAb to Participate in Three Upcoming Investor Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences over the coming weeks. H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate in a fireside chat on Wednesday, May 6th. Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28. Management will hold virtual one-on-one and small group meetings with investors on Thursday, May 28th. Jeff.
Business Wire • Apr 24, 2026

OmniAb to Report First Quarter 2026 Financial Results on May 7
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss first quarter 2026 financial results and business updates Date: Thursday, May 7, 2026 Time: 4:30 p.m. Easter.
Business Wire • Apr 21, 2026

OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
Seeking Alpha • Mar 5, 2026

OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. “OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, se.
Business Wire • Mar 4, 2026

OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.12 per share a year ago.
Zacks Investment Research • Mar 4, 2026

OmniAb to Participate at the Leerink Partners Global Healthcare Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the Leerink Global Healthcare Conference taking place March 8-11, 2026, at the W South Beach in Miami. Management will present a corporate overview on Tuesday, March 10th at 3:40 p.m. Eastern time and will hold one-on-one meetings with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their Leerink Partners repr.
Business Wire • Feb 24, 2026

¹ Disclosures

Open an M1 investment account to buy and sell OmniAb Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.